Related Experiment Video

Updated: Aug 3, 2026

Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model
06:04

Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model

Published on: June 9, 2023

Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a

Grenier1, Fioravanti, Truesdell

  • 1Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

Progress in Pediatric Cardiology
|December 15, 2000
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibitors are safe and effective for treating ventricular dysfunction in children. While data is less complete than in adults, ACE inhibitors offer a vital treatment option for pediatric patients with heart failure.

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Ventricular dysfunction and congestive heart failure (CHF) pose significant risks in infants, children, and adolescents.
  • Angiotensin-converting enzyme (ACE) inhibitors are established treatments for ventricular dysfunction in adults.

Purpose of the Study:

  • To review the causes of ventricular dysfunction and CHF in pediatric populations.
  • To evaluate the available data on ACE inhibitor use, safety, and efficacy in children.
  • To explore pharmacokinetics, mechanisms of action, and long-term outcomes of ACE inhibitors in pediatric patients.

Main Methods:

  • Literature review of randomized controlled trials and clinical data on ACE inhibitor use in pediatric patients.
  • Analysis of pharmacokinetic and pharmacodynamic properties of ACE inhibitors in children.
  • Examination of safety and efficacy data for various pediatric conditions.

Main Results:

  • ACE inhibitors demonstrate safety and efficacy in treating ventricular dysfunction in pediatric patients, though supporting data is less extensive than in adults.
  • Established benefits in adults with asymptomatic and symptomatic ventricular dysfunction are extrapolated to pediatric populations.
  • Pharmacokinetic profiles and mechanisms of action in children are reviewed, with speculation on long-term effects.

Conclusions:

  • ACE inhibitors represent a crucial therapeutic option for managing ventricular dysfunction and CHF in infants, children, and adolescents.
  • Further research is recommended to strengthen the evidence base for pediatric ACE inhibitor use.
  • Future studies should focus on long-term outcomes and optimal dosing strategies in growing children.

More Related Videos

A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition08:38

A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.